Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells

BACKGROUND: Platinum plus paclitaxel is a first-line chemotherapy for ovarian cancer. Platinum resistance is a hot topic for many scholars, but drug resistance caused by paclitaxel is also a topic of concern. Currently, scholars believe that inhibition of MAPK signaling pathway may be an effective w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Li-li, Chen, Xi, Zhang, Xiao-yu, Li, Ze-min, Fan, Xue-mei, Shen, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Lab/In Vitro Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466840/
https://www.ncbi.nlm.nih.gov/pubmed/32829374
http://dx.doi.org/10.12659/MSM.922612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466840/
https://www.ncbi.nlm.nih.gov/pubmed/32829374
http://dx.doi.org/10.12659/MSM.922612

Ejemplares similares